Durvalumab With Novel Immunotherapies Improves Progression in Locally Advanced Lung Cancer
Treatment with durvalumab, a PD-L1 inhibitor monoclonal antibody, has become established recently as the standard therapy for patients with unresectable stage III non-small cell lung cancer (NSCLC) wh...